Progress of autoimmune hemolytic anemia with chronic lymphocytic leukemia

VernacularTitle:慢性淋巴细胞白血病并发自身免疫性溶血性贫血的研究进展
Author: Xiaomu JIN ¹ ; Jianqing MI
Author Information

1. 200025,上海交通大学附属瑞金医院血液科
Keywords: Leukemia,lymphocytic,chronic; Anemia,hemolytic,autoimmune
From: Journal of Leukemia & Lymphoma 2018;27(9):573-576
CountryChina
Language:Chinese
Abstract: Autoimmune hemolytic anemia (AIHA) is a common complication of chronic lymphocytic leukemia (CLL) with a complicated pathogenesis. CLL tumor cells can trigger AIHA by directly secreting autoantibodies targeting red blood cells or by presenting erythrocyte antigens. According to the disease features of different patients, multiple treatment regimens, such as glucocorticoid, immunoglobulin, rituximab and chemotherapy containing rituximab and glucocorticoid, could be chosen. AIHA patients respond well to the treatment, but it is easy to relapse. Further studies are needed to optimize the treatment and improve the overall survival of the patients.